Confluence Wealth Services Inc. Buys New Holdings in DexCom, Inc. (NASDAQ:DXCM)

Confluence Wealth Services Inc. purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the first quarter, HoldingsChannel.com reports. The firm purchased 2,992 shares of the medical device company’s stock, valued at approximately $415,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Stableford Capital II LLC raised its position in shares of DexCom by 2.1% during the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after acquiring an additional 88 shares in the last quarter. D Orazio & Associates Inc. increased its stake in DexCom by 0.8% during the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after purchasing an additional 93 shares during the last quarter. Gulf International Bank UK Ltd raised its holdings in shares of DexCom by 0.3% during the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after purchasing an additional 93 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of DexCom by 10.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company’s stock worth $133,000 after buying an additional 98 shares during the last quarter. Finally, Harbor Investment Advisory LLC boosted its holdings in shares of DexCom by 13.1% in the 1st quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company’s stock valued at $120,000 after buying an additional 100 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

DexCom stock traded up $1.58 during trading hours on Tuesday, hitting $127.39. 3,049,135 shares of the company traded hands, compared to its average volume of 3,056,698. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The firm has a market cap of $50.66 billion, a P/E ratio of 82.19, a P/E/G ratio of 2.11 and a beta of 1.20. The firm’s 50-day simple moving average is $131.49 and its two-hundred day simple moving average is $119.53. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. As a group, analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares in the company, valued at $8,304,405.66. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $134.41, for a total transaction of $1,967,627.99. Following the sale, the chief operating officer now directly owns 273,913 shares of the company’s stock, valued at $36,816,646.33. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by company insiders.

Analysts Set New Price Targets

DXCM has been the topic of several research reports. Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Tuesday, April 23rd. Royal Bank of Canada began coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. Raymond James increased their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday. Finally, UBS Group boosted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $141.67.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.